hidradentis suppurativa
Conditions
Interventions
Interleukin-17 inhibitor treatment cohort:None
Sponsors
Department of Dermatology, Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The age is 18-80 years old, regardless of gender; 2. Patients diagnosed with moderate to severe HS (Hurley stage >= II or IHS4 score >= 4); 3. Patients deemed suitable for IL-17A inhibitor treatment by the researchers; 4. Voluntary to sign the informed consent form and able to cooperate with long-term follow-up and sample collection.
Exclusion criteria
Exclusion criteria: 1. Age80 years old; 2. Have medical conditions that contraindicate the use of IL-17A inhibitors (such as history of allergy to the components of the study drug, inflammatory bowel disease, pregnancy or lactation); 3. Have active infections (such as viral hepatitis, active tuberculosis); 4. Have any medical or mental conditions that the investigator deems would prevent the patient from completing the study according to the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects with Hidradenitis Suppurativa achieving clinical response (HiSCR) after 16 weeks of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean percentage of changes in abscess and nodule (AN) count ;Changes in IHS4 scores of subjects;Improvement in the Dermatology Life Quality Index (DLQI) ;Changes in numerical rating scale (NRS) for pain before and after treatment; | — |
Countries
China
Contacts
Public ContactWenhui Wang
Department of Dermatology, Peking University Third Hospital
Outcome results
None listed